Beginning with its exatecan ADC, STRO-004, aimed at Tissue Factor, the biotechnology company situated in South San Francisco ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s ...

It is easy to overlook how much coordination, time and dedication goes into running a college campus and ensuring everything ...

Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as ...

ImmunoPrecise announced a partnership with a biotechnology giant to develop ADCs and bispecific antibodies for the treatment ...

ImmunoPrecise Antibodies (IPA) announces a strategic partnership with a leading biotechnology company with a multi-billion-dollar market ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A ...

The partnership combines AbTis' AbClick site-selective conjugation platform with WuXi XDC's all-in-one development and ...

ADCs have transformed bladder cancer treatment, but challenges like toxicity management and high costs remain significant hurdles. ADCs vary in components and mechanisms, influencing outcomes and ...

Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s Keytruda-challenging ivonescimab in combination with several of its antibody-drug conjugates (ADCs).